Wave Life Sciences Ltd.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
During the three months ended December 31, 2025, certain of our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors entered into contracts, instructions or written plans (each, a “Rule 10b5-1 Trading Plan” and collectively, the “Rule 10b5-1 Trading Plans”) for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We describe the material terms of these Rule 10b5-1 Trading Plans below.
On November 21, 2025, Paul B. Bolno, M.D., MBA, our President and Chief Executive Officer, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 1,480,900 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Bolno's Rule 10b5-1 Trading Plan is active until June 16, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On November 20, 2025, Christopher Francis, Ph.D., our Senior Vice President, Corporate Development, Head of Emerging Areas, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 520,702 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Francis’ Rule 10b5-1 Trading Plan is active until August 21, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On December 17, 2025, Kyle Moran, CFA, our Chief Financial Officer, terminated a Rule 10b5-1 Trading Plan that was originally adopted on November 20, 2025. Mr. Moran’s former Rule 10b5-1 Trading Plan provided for the sale of up to an aggregate of 392,647 of our ordinary shares. No ordinary shares were sold under Dr. Moran’s Rule 10b5-1 Trading Plan prior to its termination.
On December 18, 2025, Mr. Moran adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 196,647 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Mr. Moran's Rule 10b5-1 Trading Plan is active until August 21, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On December 16, 2025, Chandra Vargeese, Ph.D., our Chief Technology Officer, Head of Platform Discovery Sciences, terminated a Rule 10b5-1 Trading Plan that was originally adopted on November 19, 2025. Dr. Vargeese’s former Rule 10b5-1 Trading Plan provided for the sale of up to an aggregate of 132,886 of our ordinary shares. No ordinary shares were sold under Dr. Vargeese’s Rule 10b5-1 Trading Plan prior to its termination.
On December 17, 2025, Dr. Vargeese adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 82,886 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Vargeese’s Rule 10b5-1 Trading Plan is active until August 20, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
Except as disclosed above, none of our directors or executive officers adopted, modified orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as such term is defined in Item 408(a) of Regulation S-K, during the fiscal quarter ended December 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.